Pacer Advisors, Inc. Biocryst Pharmaceuticals Inc Transaction History

Pacer Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.13 - $6.79 $19,233 - $31,621	-4,657 Reduced 63.74%	2,649 $16,000
Q1 2024 May 10, 2024	BUY	$4.89 - $7.65 $35,726 - $55,890	7,306 New	7,306 $37,000
Q2 2021 Jul 21, 2021	SELL	$9.5 - $17.24 $58,681 - $106,491	-6,177 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$7.37 - $13.61 $71,990 - $132,942	-9,768 Reduced 61.26%	6,177 $63,000
Q4 2020 Jan 20, 2021	SELL	$3.37 - $8.61 $28,840 - $73,684	-8,558 Reduced 34.93%	15,945 $119,000
Q3 2020 Oct 19, 2020	BUY	$3.43 - $5.53 $84,045 - $135,501	24,503 New	24,503 $84,000
Q4 2018 Feb 13, 2019	SELL	$6.51 - $9.6 $46,598 - $68,716	-7,158 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $39,512 - $57,192	7,158 New	7,158 $55,000
Q1 2018 May 14, 2018	SELL	$4.35 - $5.82 $9,135 - $12,222	-2,100 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$4.16 - $5.33 $8,736 - $11,193	2,100	2,100 $10,000

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.